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Original StudieS
Background: Bordetella pertussis can cause severe respiratory disease and 
death in children. In recent years, large outbreaks have occurred in high-
income countries; however, little is known about pertussis incidence in 
sub-Saharan Africa.
Methods: We evaluated antibody responses to pertussis toxin (Ptx) from 
individuals aged between 2 and 90 years in rural Gambia. IgG-Ptx was 
measured using luminex xMAP technology. IgG-Ptx geometric mean con-
centrations (GMC) and their 95% confidence intervals were calculated. 
The proportion seropositive (>20 EU/mL or ≥62.5 EU/mL) and GMCs 
were compared by age, sex, ethnic group, vaccination status, birth order 
and number of siblings per household using logistic and linear regression.
Results: 76.3% had anti-Ptx levels <20 EU/mL, 17.5% had concentrations 
between 20 and 62.5 EU/mL, 4.4% had concentrations between 62.5 and 125 
EU/mL and 1.8% had concentrations ≥125 EU/mL. The overall Ptx antibody 
GMC was 6.4 EU/mL (95% confidence interval: 5.8–6.9). Higher antibody 
concentrations were observed in older populations with evidence for an 
increase in infection risk with increasing age (1.9% yearly increase, 95% 
confidence interval: 1.3–2.5). No child under 6 years of age had GMC above 
62.5 EU/mL but 29.5% had concentrations between 20 and 62.5 EU/mL.
Conclusions: These data provide evidence that B. pertussis is being trans-
mitted within this population despite high vaccination coverage. Re-infec-
tion may occur implying that immunity from childhood vaccination may 
not be lifelong. In the absence of data on actual clinical cases of pertus-
sis, seroprevalence studies remain valuable tools to assess the transmission 
dynamics of B. pertussis.
Key Words: pertussis, whooping cough, seroprevalence, sub-Saharan 
Africa, vaccine
(Pediatr Infect Dis J 2015;34:333–338)
The bacterium Bordetella pertussis which causes whooping cough can lead to severe respiratory disease and death mainly 
in infants. Recent mathematical models suggest that annually 16 
million cases of pertussis occur worldwide, with 95% in low-
income countries,1 and an estimated 81,400 die from this disease.2 
The introduction of whole cell pertussis vaccines (WCVs) in the 
1950s in industrialized countries resulted in a dramatic decrease 
in pertussis cases. Although efficacious, reactogenicity of WCVs 
led to suboptimal vaccine uptake, therefore, less reactogenic acel-
lular vaccines (ACVs) were introduced.3 However, recent large 
outbreaks among infants and adults have been observed in several 
high-income countries.3–5 This resurgence of pertussis has most 
likely arisen through a combination of factors: improved diagnos-
tics; pathogen adaptation which may have reduced the efficacy of 
pertussis vaccines6; waning immunity occurring after vaccination; 
vaccination which induces short duration of protection compared 
with natural infection with B. pertussis and finally, there is now 
evolving evidence to suggest that immunity induced by ACVs is 
less long lasting compared with WCVs vaccines.7–9
The substantial increase especially among adolescents 
and young adults, despite high vaccination coverage,5,10,11 is of 
public health concern as these individuals are important sources 
of infection for infants too young to be (fully) vaccinated.12,13 In 
high-income countries, young infants account for the majority of 
hospital admissions for pertussis and incidence in this age group is 
increasing.3,4,14These changes in the epidemiology of pertussis have 
raised concern that current vaccination strategies against pertussis 
might not be optimal and alternative strategies such as adolescent 
booster vaccinations, cocooning or maternal vaccination are now 
being considered and already implemented in some settings.1
To understand to what extent the findings from industrial-
ized countries also reflect the situation in sub-Saharan Africa and 
whether pertussis has re-emerged as a threat in a population vac-
cinated with a WCV only, insight into the levels of infection in 
populations is required. However, there have been only a few stud-
ies in Africa: they were conducted either in the context of a vaccine 
trial,15,16 or hospital-based and provide no information on less severe 
or subclinical cases17 or focused only on children under 10 years of 
age.18 To assess immunity and potential susceptibility to pertussis at 
population levels, we evaluated antibody concentrations to pertus-
sis toxin (Ptx) in a cross-sectional study in sera from individuals 
aged between 2 and 90 years of age living in rural Gambia.
MATERIALS AND METHODS
Study Area and Population
Antibody concentrations against pertussis were measured 
in banked serum samples of an existing longitudinal cohort. This 
prospective cohort was created in 1984, when HBV vaccination 
was initiated in two Gambian villages in the Kiang West region 
(Keneba and Manduar). Since then, cross-sectional serological 
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surveys at approximately 4- to 5-year intervals have been con-
ducted to assess long-term HBV vaccine effectiveness.19 At time 
of the original 2008 survey informed consent was given for use 
of stored blood samples for additional research. Stored samples 
from the 2008 serosurvey from adults and children aged >2 years 
of age were available to us. For children below the age of 2, a 
finger prick sample was collected and no serum remained for 
this study, hence this age group could not be included. For the 
remainder of the population, an age stratified sample was ran-
domly selected, powered to achieve a 3% confidence interval 
(CI) for an estimate 5% seroprevalence. The current Expanded 
Programme on Immunisation schedule for the Gambia uses 
threedoses of the Pentavalent vaccine [Diphtheria–Tetanus–
whole cell Pertussis (DTwP)–hepatitis B(HepB)-Hib] at 2, 3 and 
4 months. A further fourth dose of DTwP is also given routinely 
at 18 months of age.20
Laboratory Methods
The banked sera were stored at -80°C until the time of test-
ing. IgG antibodies directed against pertussis toxin (IgG-Ptx) were 
measured using luminex xMAP technology with a validated multi-
plex immunoassay for diphtheria, tetanus and pertussis as described 
previously.21 In brief, reconstituted freeze-dried Ptx (National Insti-
tute for Biological Standards and Control, South Mimms, United 
Kingdom) was conjugated to activated carboxylated microsphere 
(Bio-plex COOH beads, Bio-rad, Hemel Hempstead, United 
Kingdom) following published methods.22 The in-house pertussis 
standard (calibrated against the US reference pertussis anti-serum 
human lot 3 FDA) was diluted fourfold in 6 dilution steps (1:200–
1:204,800), whereas unknown sera were diluted 1:200 and 1:4000. 
The detection antibody, goat anti-human IgG (ƴ chain specific) 
R-phycoerythrin conjugated (Jackson ImmunoResearch Laborato-
ries Inc., Westgrove, PA) was diluted 1:200. Results were generated 
with a Bio-plex 200 system in combination with Bio-plex Manager 
software (version 4.1.1, Bio-rad, United Kingdom). Median fluo-
rescent intensity was converted to EU/mL by interpolation from a 
5-parameter logistic standard curve.
IgG-Ptx concentrations have been widely used to assess 
the prevalence of B. pertussis infections. Previous studies show 
that concentrations of anti-Ptx antibodies ≥62.5 and ≥125 EU/mL 
were evidence of a previous infection in the past 12 and 6 months, 
respectively.11,23–25 We categorized anti-Ptx IgG levels into 4 groups 
according to the estimated average time since infection; 0 to <20 
EU/mL (no recent infection), 20 to <62.5 EU/mL (infection pos-
sibly more than a year ago and/or vaccination response), 62.5 to 
<125 (infection in the last year) and ≥125 EU/mL (infection in the 
past 6 months).
Statistical Analyses
Logarithms of anti-Ptx IgG levels and antibody geometric 
mean concentrations (GMC) and their 95% CIs were calculated. 
The proportion of seropositivity and GMCs were compared by 
age group. Logistic regression and χ2 tests were used to compare 
and test the statistical significant of the difference of Ptx seropos-
itivity (as defined by ≥20 or ≥62.5 EU/mL) between covariates 
of interest (age, sex, ethnic group, vaccination status, birth order 
and number of siblings per household). Student’s t test and linear 
regression were used to estimate differences in log concentra-
tions between covariate groups. Covariates were retained in the 
model if associations were observed at the P < 0·05 level and/or 
if they altered substantially the associations of other effect vari-
ables in multivariable analysis. Data on DwPT vaccination status 
were only systematically available for those born after January 1, 
1996; thus, the above analysis was repeated to include vaccina-
tion status and restricted to this age group. Statistical analyses 
were performed using STATA 12·0 statistical software (http://
www.stata.com).
Ethical Approval
Approval was obtained from The Government of The Gam-
bia/Medical Research Council Joint Ethics Committee (SCC1261).
RESULTS
A total of 1893 individuals from Keneba and Manduar 
were included in the initial 2008 HBV serosurvey. One thousand 
and sixty-seven (56·4%) of these samples were randomly selected 
throughout all age categories and included in this analysis. The gen-
eral characteristics of the study population and levels of Ptx con-
centrations are shown in Table 1. 95.5% were of Mandinka ethnic 
origin. Available data with vaccine records in the cohort (n = 298) 
show that 86% had received at least one dose and 77% at least 3 
doses of DwPT vaccine (Table, Supplemental Digital Content 1, 
http://links.lww.com/INF/C30).
TABLE 1. General Characteristics of the Keneba and Manduar Population, 2008 Serosurvey
Total, N %<20 EU/mL %≥20 to <62.5 EU/mL %≥62.5 to <125 EU/mL %≥125 EU/mL
Overall 1067 76.3 17.5 4.4 1.8
Male 462 76.6 16.0 5.2 2.2
Female 605 76.0 18.7 3.8 1.5
Age group
 <4.99* 93 71.0 29.0 0 0
 5–9.99 128 78.9 15.6 3.9 1.6
 10–14.99 121 82.6 9.9 4.1 3.3
 15–19.99 129 74.4 17.1 5.4 3.1
 20–24.99 110 79.1 12.7 5.5 2.7
 25–29.99 201 86.1 10.5 2.5 1
 30–49.9 215 66.5 26.1 6.1 1.4
 50+ 67 68.7 20.9 9.0 1.5
Missing data 3 66.7 33.3 0 0
No of DPT doses recorded for those born after Jan 1, 1996 (n = 298)
 0 41 80.5 12.2 2.4 4.9
 1 13 53.9 30.8 7.7 7.7
 2 14 71.4 28.6 0 0
 3 86 76.7 17.4 3.5 2.3
 4 144 79.2 18.8 2.1 0
*Minimum age for <5 is 2.2 years.
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Ptx IgG Antibody Levels
Overall, 76·3% had anti-Ptx concentrations <20 EU/mL, 
17.5% had concentrations between 20 and 62.5 EU/mL, 4.4% had 
concentrations between 62.5 and 125 EU/mL. Fewer than 2% of the 
population had concentrations ≥125 EU/mL. Ptx IgG concentra-
tions by age groups are shown in Figures 1 and 2.
Overall Ptx antibody GMC was 6·4 EU/mL (95% CI: 5.8–
6.9), but 6.2% had anti-Ptx antibody concentrations ≥62.5 EU/
mL (Fig. 3). Increasing age was associated with increasing GMC 
(1.9 % yearly increase, 95% CI: 1.3–2.5). The odds of having anti-
body concentrations ≥62.5 EU/mL were greater among those over 
50 years of age compared with those younger than 10 years [odds 
ratio: 10·4 (95% CI: 4.3–20.3)]. There was no evidence for other 
risk factors (gender, ethnic group, birth order or sibling order) asso-
ciated with Ptx antibody concentrations and therefore no multivari-
able analysis was performed (Table, Supplemental Digital Content 
2, http://links.lww.com/INF/C29).
For those born after January 1, 1996, 22.8% (95% CI: 18–28) 
of children less than 13 years of age had anti-Ptx antibody concen-
trations ≥20 EU/mL. The overall anti-Ptx antibody GMC was 4.9 
EU/mL (95% CI: 4.1–5.8) (Table, Supplemental Digital Content 1, 
http://links.lww.com/INF/C30). No child under 6 years of age (0/93) 
had GMC above 62.5 EU/mL but 29.5% (95% CI: 21.8–38.1) had 
concentrations between 20 and 62·5 EU/mL. Children aged between 
6 and 10 years had lower odds of having concentrations above 20 
EU/mL (OR: 0.5, 95% CI: 0.3–1.0) and a 35.5% (95% CI: 3.9–
56.7) decrease in GMC compared with children aged less than 6 
years of age. This association was not observed among those aged 
between 10 and 13 years (P = 0·069). Being Mandinka was associ-
ated with lower antibody concentrations [47·2% decrease (95% CI: 
3.7–71.0)]. There was no evidence for other risk factors (gender, 
birth order, number of siblings per household or the number of DPT 
doses recorded) associated with Ptx antibody concentrations and 
therefore no multivariable analysis was performed (Table, Supple-
mental Digital Content 1, http://links.lww.com/INF/C30).
DISCUSSION
Our data from a 2008 rural population cohort of over 1000 
individuals aged between 2 and 90 years in The Gambia showed 
that 6% of individuals had antibody concentrations indicative of 
a pertussis infection within the last year (≥62.5 EU/mL). These 
data provide evidence that B. pertussis continues to be transmit-
ted within this population despite high vaccination coverage. High 
IgG-Ptx concentrations (≥62.5 EU/mL) are a highly specific crite-
rion for a pertussis infection within the last year.24 Following infec-
tion with B. pertussis, an increase of IgG-Ptx is observed which 
reaches a maximum within a few weeks and then declines steadily 
for 6–12 months after infection.26 Interpretation of IgG-Ptx con-
centrations is complicated by the fact that all pertussis vaccines 
contain Ptx. However, most WCVs hardly induce IgG-Ptx antibod-
ies and high concentrations of IgG-Ptx induced by ACVs rapidly 
wane within 6 months.23 The definitive level of antibodies required 
to protect against pertussis infection is not established, and evi-
dence indicates an additional role of T-cell mediated immunity.27,28 
Unfortunately, no samples were available to conduct T cell-based 
stimulation assays in this Gambian cohort.
Despite the population differences, our results are com-
parable with data from a resource-rich country: a seroprevalence 
study conducted in the Netherlands in 1995/1996 by our co-authors 
using samples of WCV vaccinated individuals analyzed with iden-
tical laboratory methods showed that 4.0% of individuals (95% CI: 
3.3–4.7) above >9 years of age had IgG-Ptx concentrations ≥62.5 
EU/mL.11 For both studies, MIA Luminex was used, the correla-
tion between MIA and Elisa was excellent in previous studies, and 
cut-off values are similar for both assays and based on the same 
international standard.11,21,29
FIGURE 1. Concentrations of Ptx IgG by age group for those with vaccination records (born after January 1, 1996), 2008 
serosurvey in Keneba and Manduar, Kiang West Region, The Gambia. Numbers on top of bars Total number sampled by age 
group.
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FIGURE 2. Concentrations of Ptx IgG by age group for those without vaccination records (born before January 1, 1996), 
2008 serosurvey in Keneba and Manduar, Kiang West Region, The Gambia. Numbers on top of bars Total number sampled by 
age group.
FIGURE 3. Proportion with Ptx IgG concentration ≥62.5 EU/mL by age group in years: reflecting infection within the last 
year, 2008 serosurvey in Keneba and Manduar, Kiang West Region, The Gambia. Vertical bars 95% CIs, numbers on top of 
bars total number sampled by age group.
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Pertussis vaccine update in our cohort was generally high. 
The Expanded Programme on Immunisation was initiated in The 
Gambia in May 1979, initially administering BCG, Diphtheria–Tet-
anus–whole cell Pertussis (DTwP), measles, oral polio and yellow 
fever. HepB vaccine was phased in between 1986 and 1990 with 
Haemophilus influenzae type b (Hib) vaccine added to the sched-
ules in 1997. In 2009, the pentavalent vaccine (DwPT-HepB-Hib) 
was introduced, and lately PCV13 and rotavirus vaccination were 
added. Data from our demographic surveillance system in Kiang 
West between 2005 and 2012 show that in general, over 95% of 
infants received 3 doses of DwPT and 83% of infants received a 
fourth dose.20 These data are comparable with our study partici-
pants albeit with slightly lower coverage in our study population; 
in children <6 years of age, 93% were vaccinated with at least one 
dose of DwPT and 81.4% had received 3 or 4 doses. No child in this 
age group showed serological evidence of recent pertussis infec-
tion, possibly as they remain protected by the primary immuniza-
tions. In children aged between 6 and 10 years, overall anti-Ptx IgG 
concentrations were lower compared with the younger age group 
and 5.5% in this age group had concentrations ≥62.5 EU/mL. Both 
of these observations suggest waning of vaccine-induced immu-
nity and evidence for increasing susceptibility to wild-type infec-
tion. The lack of very high concentrations observed in younger age 
groups could potentially be due to a blunted response, due to recent 
vaccination and hence resulting in less severe infection.
The higher antibody concentrations observed in the older age 
groups are consistent with increased risk of infection with increasing 
age, implying that immunity from childhood vaccination or disease 
may not be lifelong. However, because it is not possible to distin-
guish between antibodies induced by vaccination or infection using 
our current assays, it is also plausible that observed Ptx antibody 
concentrations may be the result of natural boosting. Our findings 
are consistent with previous studies in Senegal,18 and further add to 
the evidence that the current pertussis vaccination strategies in sub-
Saharan Africa may not be sufficient to provide long-term immunity. 
Alternatively increasing antibody levels with age could be due to 
age-related cumulative exposure to B. pertussis over time, possibly 
resulting in boosting of specific memory immune responses by con-
tinuous encounters with B. pertussis antigens.30
Because there are no current data on pertussis incidence or 
case-fatality rates from low-income countries, expert opinion and 
modeling remain as the only methods available to provide such esti-
mates.2 Only one study in the 1980s to mid-1990s from Senegal car-
ried out active surveillance within communities to measure changes 
in pertussis incidence pre- and post-vaccination introduction.15,16 Chil-
dren less than 15 years of age were followed over a 13-year period 
for the occurrence of pertussis.16 The crude pertussis incidence before 
vaccination was 183 per 1000 child-years, with a 2.8% case-fatality 
rate. After the introduction of the vaccination program, overall inci-
dence dropped by 27% after 3 years and 46% after 6 years. A recent 
hospital study from Niger has reported 11.2% out of 305 children aged 
<5 years admitted with respiratory symptoms at the National Hospital 
of Niamey were positive for a Bordetella species detected by PCR, 
but only 1.3% were positive for B. pertussis.17 The more recent Sen-
egalese population-based data reported no cases of pertussis disease 
in children less than 10 years of age.18 Anecdotally and according to 
hospital admission data, very little pertussis disease is being observed 
in any age group in The Gambia (Dr. S. Anderson, Head of Clinical 
Services, MRC Unit-The Gambia, personal communication). Misdi-
agnosis could be an important reason for the lack of clinical diagnosis 
of pertussis in The Gambia and other similar settings, as well as pos-
sibly underreporting of milder cases which may not be considered 
severe enough to report to health facilities, particularly in an African 
rural context.18 Pertussis diagnosis in adolescents and adults is often 
delayed or missed because of mild symptoms.3 Pertussis in infants 
can also present atypically; there may be no cough,17 and children 
may die from extreme leukocytosis and pulmonary hypertension or 
even other causes (later) due to weight loss and secondary infections. 
Thus, without laboratory confirmation the cause of severe morbidity 
or death can often not be attributed directly to a pertussis infection. 
This remains a challenge in particular in resource-poor settings.
An important question is whether WCV may be better at 
preventing severe disease compared with ACV when given dur-
ing childhood, even if not preventing infection.7,9 Evolving evi-
dence suggests that immunity induced by ACVs is less long last-
ing compared with WCVs vaccines.7–9 Infant priming with WCV 
has been shown to be associated with a lower risk of subsequent 
pertussis than ACV only primed infants,7,9 with the effect of protec-
tion through WCV persisting for more than a decade.9 Long-term 
protection against disease was also observed when immunity was 
induced by natural infection, and evidence from human and animal 
studies suggest that natural infection is more effective than vac-
cination in conferring protection against subsequent (secondary) 
infection. The baboon model of pertussis suggests that both WCV- 
and ACV-immunized baboons can be re-infected, but B. pertussis 
is cleared faster in the former group.8 Further studies of immunity 
in countries where WCVs are still used, such as the Gambia, will 
provide an opportunity to further clarify the interdependence of 
cellular and humoral mechanisms of protection.
Very little is known about currently circulating strain types 
in the Gambia and their virulence factors in comparison to those in 
higher income countries. Further studies of strain diversity and its 
impact on host responses may be warranted to compare populations 
that use either WCV or ACV to better understand the epidemio-
logical differences between high- and low-income countries, and to 
guide public health efforts to protect the population against severe 
pertussis infections.
In conclusion, our serological study shows that B. pertussis 
is still circulating within populations of The Gambia. In the absence 
of data on actual clinical cases of pertussis, seroprevalence stud-
ies remain valuable tools to assess the transmission dynamics of 
B. pertussis. However, without data from case findings studies the 
long-term impact of vaccination on pertussis incidence and severity 
of illness in low-income countries remains unclear.
ACKNOWLEDGMENTS
The authors extend their thanks to the residents of Keneba 
and Manduar villages in the Kiang West Region of the Gambia 
who agreed to take part in the 2008 serosurvey. The authors also 
acknowledge Sabine de Greeff for her valuable input and discus-
sions in the design of this study. Sir Andy Hall, Hilton Whittle, 
Sophie Moore, the data and field team at MRC Keneba and all 
those involved in the Hepatitis B cohort.
REFERENCES
 1. Pertussis vaccines: WHO position paper. Wkly Epidemiol Rec. 2010;85:385–
400.
 2. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 
235 causes of death for 20 age groups in 1990 and 2010: a systematic analy-
sis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095–
128.
 3. Wood N, McIntyre P. Pertussis: review of epidemiology, diagnosis, manage-
ment and prevention. Paediatr Respir Rev. 2008;9:201–211.
 4. Galanis E, King AS, Varughese P, et al; investigators I. Changing epidemiol-
ogy and emerging risk groups for pertussis. CMAJ. 2006;174:451–452.
 5. Celentano LP, Massari M, Paramatti D, et al. Resurgence of pertussis in 
Europe. Pediatr Infect Dis J. 2005;24:761–765.
 6. Mooi FR, Van Der Maas NA, De Melker HE. Pertussis resurgence: waning 
immunity and pathogen adaptation - two sides of the same coin. Epidemiol 
Infect. 2014;142:685–694.
Scott et al The Pediatric Infectious Disease Journal • Volume 34, Number 4, April 2015
338  |  www.pidj.com  © 2014 Wolters Kluwer Health, Inc. All rights reserved.
 7. Liko J, Robison SG, Cieslak PR. Priming with whole-cell versus acellular 
pertussis vaccine. N Engl J Med. 2013;368:581–582.
 8. Warfel JM, Zimmerman LI, Merkel TJ. Acellular pertussis vaccines protect 
against disease but fail to prevent infection and transmission in a nonhuman 
primate model. Proc Natl Acad Sci USA. 2014;111:787–792.
 9. Sheridan SL, Ware RS, Grimwood K, et al. Number and order of 
whole cell pertussis vaccines in infancy and disease protection. JAMA. 
2012;308:454–456.
 10. Skowronski DM, De Serres G, MacDonald D, et al. The changing age and 
seasonal profile of pertussis in Canada. J Infect Dis. 2002;185:1448–1453.
 11. de Greeff SC, de Melker HE, van Gageldonk PG, et al. Seroprevalence 
of pertussis in The Netherlands: evidence for increased circulation of 
Bordetella pertussis. PLoS One. 2010;5:e14183.
 12. de Greeff SC, Mooi FR, Westerhof A, et al. Pertussis disease burden in 
the household: how to protect young infants. Clin Infect Dis. 2010;50: 
1339–1345.
 13. Kowalzik F, Barbosa AP, Fernandes VR, et al. Prospective multinational 
study of pertussis infection in hospitalized infants and their household con-
tacts. Pediatr Infect Dis J. 2007;26:238–242.
 14. Tanaka M, Vitek CR, Pascual FB, et al. Trends in pertussis among infants in 
the United States, 1980–1999. JAMA. 2003;290:2968–2975.
 15. Simondon F, Preziosi MP, Yam A, et al. A randomized double-blind trial 
comparing a two-component acellular to a whole-cell pertussis vaccine in 
Senegal. Vaccine. 1997;15:1606–1612.
 16. Preziosi MP, Yam A, Wassilak SG, et al. Epidemiology of pertussis in a West 
African community before and after introduction of a widespread vaccina-
tion program. Am J Epidemiol. 2002;155:891–896.
 17. Jusot V, Aberrane S, Ale F, et al. Prevalence of Bordetella infection in a 
hospital setting in Niamey, Niger. J Trop Pediatr. 2014;60:223–230.
 18. Gaayeb L, Sarr JB, Ndiath MO, et al. Seroprevalence of pertussis in Senegal: 
a prospective study. PLoS One. 2012;7:e48684.
 19. Mendy M, Peterson I, Hossin S, et al. Observational study of vaccine effi-
cacy 24 years after the start of hepatitis B vaccination in two Gambian vil-
lages: no need for a booster dose. PLoS One. 2013;8:e58029.
 20. Scott S, Odutola A, Mackenzie G, et al. Evaluation of the EPI programme in 
the Gambia: implications of the current immunisation schedule and for new 
vaccine introduction. PLoS One.2014;9:e107280.
 21. van Gageldonk PG, van Schaijk FG, van der Klis FR, et al. Development and 
validation of a multiplex immunoassay for the simultaneous determination of 
serum antibodies to Bordetella pertussis, diphtheria and tetanus. J Immunol 
Methods. 2008;335:79–89.
 22. Staros JV, Wright RW, Swingle DM. Enhancement by 
N-hydroxysulfosuccinimide of water-soluble carbodiimide-mediated cou-
pling reactions. Anal Biochem. 1986;156:220–222.
 23. Hallander HO, Ljungman M, Storsaeter J, et al. Kinetics and sensitiv-
ity of ELISA IgG pertussis antitoxin after infection and vaccination with 
Bordetella pertussis in young children. APMIS. 2009;117:797–807.
 24. de Melker HE, Versteegh FG, Conyn-Van Spaendonck MA, et al. Specificity 
and sensitivity of high levels of immunoglobulin G antibodies against 
pertussis toxin in a single serum sample for diagnosis of infection with 
Bordetella pertussis. J Clin Microbiol. 2000;38:800–806.
 25. de Greeff SC, Teunis P, de Melker HE, et al. Two-component cluster anal-
ysis of a large serodiagnostic database for specificity of increases of IgG 
antibodies against pertussis toxin in paired serum samples and of absolute 
values in single serum samples. Clin Vaccine Immunol. 2012;19:1452–1456.
 26. Hallander HO, Gustafsson L, Ljungman M, et al. Pertussis antitoxin decay 
after vaccination with DTPa. Response to a first booster dose 3 1/2-6 1/2 
years after the third vaccine dose. Vaccine. 2005;23:5359–5364.
 27. Mahon BP, Brady MT, Mills KH. Protection against Bordetella pertussis 
in mice in the absence of detectable circulating antibody: implications for 
long-term immunity in children. J Infect Dis. 2000;181:2087–2091.
 28. Higgins SC, Jarnicki AG, Lavelle EC, et al. TLR4 mediates vaccine-induced 
protective cellular immunity to Bordetella pertussis: role of IL-17-producing 
T cells. J Immunol. 2006;177:7980–7989.
 29. European Centre for Disease Prevention and Control. External quality assur-
ance scheme for Bordetella pertussis serology 2013. Stockholm: ECDC;2014.
 30. Versteegh FG, Mertens PL, de Melker HE, et al. Age-specific long-term 
course of IgG antibodies to pertussis toxin after symptomatic infection with 
Bordetella pertussis. Epidemiol Infect. 2005;133:737–748.
